A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

Summary

The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.

Timeline

Start

2007-02

Primary completion

2011-02

Completion

2012-01

Drugs

Indications